Ataxia-Telangiectasia (AT)
Table of Contents
- What Ataxia-Telangiectasia Is
- The ATM Gene: Master Regulator of DNA Repair
- Cerebellar Ataxia: Neurological Decline
- Telangiectasias: The Diagnostic Hallmark
- Immunodeficiency in AT
- Cancer Susceptibility and Radiation Sensitivity
- Alpha-Fetoprotein and Diagnosis
- Treatment and Supportive Care
- Heterozygous ATM Carriers: Family Risk
- Living with AT: Practical Guidance
- Key Research Papers
- Connections
- Featured Videos
What Ataxia-Telangiectasia Is
Ataxia-Telangiectasia (AT), also known as Louis-Bar Syndrome, is a rare inherited disease that damages the nervous system, weakens the immune system, and dramatically raises the risk of cancer — all because of a single broken gene. It is one of the most complex multi-system diseases in medicine, touching neurology, immunology, and oncology simultaneously. Understanding AT requires understanding what that one gene normally does and what happens to the body when it stops working.
AT is inherited in an autosomal recessive pattern, meaning a child must inherit two defective copies of the ATM gene — one from each parent — to develop the disease. Parents who each carry one defective copy are healthy carriers and typically have no idea they carry the mutation until an affected child is born. The gene responsible sits on chromosome 11q22.3. AT affects approximately 1 in 40,000 to 100,000 live births worldwide. It strikes boys and girls equally, and its effects begin in early childhood, typically becoming apparent in the first two years of life when a child starts to walk.
The name describes its two most visible features: ataxia (loss of muscle coordination and balance) and telangiectasias (clusters of permanently dilated, spider-like blood vessels visible in the eyes and skin). But these visible signs are only part of the picture. Beneath them, AT causes profound DNA repair failure that silently accumulates damage in neurons, immune cells, and throughout the body — creating the conditions for both progressive neurological decline and markedly elevated cancer risk.
Despite its severity, AT is frequently misdiagnosed in the early years as cerebral palsy, multiple sclerosis, or a simple coordination problem. Recognizing the full pattern — particularly the combination of progressive ataxia, recurrent infections, and elevated alpha-fetoprotein — is essential for early diagnosis and appropriate management.
The ATM Gene: Master Regulator of DNA Repair
The ATM gene encodes a large protein called ATM kinase — a serine-threonine kinase that serves as the master regulator of the cellular response to DNA double-strand breaks (DSBs). A DNA double-strand break is one of the most dangerous forms of genetic damage: both strands of the DNA helix are severed simultaneously, and if the break is not repaired correctly, the result is chromosomal rearrangements, mutations, or cell death.
When a double-strand break occurs in a healthy cell, ATM is one of the first proteins activated. It works by phosphorylating — chemically tagging — a cascade of downstream proteins that coordinate the cell's response:
- H2AX (forming γH2AX foci): ATM phosphorylates the histone variant H2AX at the site of the break, creating a molecular beacon that marks the damage location and recruits DNA repair machinery.
- p53: ATM activates the tumor suppressor p53, which can halt cell division (giving time for DNA repair) or trigger programmed cell death (apoptosis) if damage is irreparable.
- CHK2: ATM phosphorylates the checkpoint kinase CHK2, which enforces the S-phase and G2/M cell cycle checkpoints — preventing the cell from copying or dividing until its DNA is repaired.
- BRCA1: ATM activates BRCA1, a key scaffold protein in homologous recombination repair, the high-fidelity repair pathway that uses an identical DNA template to correctly restore the broken sequence.
Without functional ATM, this entire coordinated response fails. Cells with double-strand breaks continue dividing before their DNA is repaired. Damage accumulates with each cell cycle. Over time, three consequences emerge: neurons die (Purkinje cells in the cerebellum are especially vulnerable), immune cells malfunction (T- and B-cell development requires DNA rearrangements that ATM normally supervises), and cancer develops (accumulated chromosomal instability and failed apoptosis allow malignant cells to proliferate unchecked).
The ATM protein is also critical during the process of V(D)J recombination — the DNA rearrangement that immune cells use to generate the enormous diversity of T-cell receptors and B-cell antibodies. This process requires deliberately cutting and rejoining DNA strands. Without ATM, these programmed cuts are misrepaired, explaining why chromosomal instability in AT is particularly concentrated at the sites of T-cell receptor (chromosomes 7 and 14) and immunoglobulin genes.
Cerebellar Ataxia: Neurological Decline
The neurological component of AT is typically the first sign that something is wrong. Most children with AT appear to develop normally through infancy, but as they begin to walk — usually around ages 1–2 — parents and clinicians notice that their balance is off. The walk is unsteady, lurching, or wide-based. This is cerebellar ataxia: loss of coordination caused by the progressive death of neurons in the cerebellum, the brain region responsible for fine motor control, balance, and smooth movement coordination.
Cerebellar Purkinje Cell Loss
The neurons most severely affected are Purkinje cells — the large, elaborate neurons that are the primary output cells of the cerebellar cortex. Purkinje cells are exquisitely sensitive to DNA damage because they do not regenerate. Once lost, they are gone permanently. In AT, the failure of ATM to repair DNA double-strand breaks leads to progressive Purkinje cell death throughout childhood and adolescence. As Purkinje cells disappear, the cerebellum loses its ability to fine-tune movement signals, producing progressively worsening ataxia.
Progression Over Time
The trajectory of neurological decline is predictable but varies in pace among individuals. Early in childhood, ataxia may be subtle enough that it is dismissed as normal toddler clumsiness. By school age, the unsteady gait is unmistakable. Most children with AT require a wheelchair by ages 10 to 15 as their legs lose the coordination needed for safe walking. Upper-limb coordination deteriorates in parallel, making tasks like writing, eating, and self-care progressively harder.
Other Neurological Features
Beyond gait ataxia, AT produces several characteristic neurological signs:
- Oculomotor apraxia: Difficulty initiating smooth eye movements toward a target. Instead of the eyes moving first, children with AT characteristically thrust their head in the direction they want to look, then let their eyes follow — a distinctive compensatory strategy.
- Dysarthria: Slurred, slow, or poorly coordinated speech caused by cerebellar control of the muscles involved in speaking.
- Choreiform movements: Involuntary, irregular, writhing movements that may appear in the hands and face as the disease progresses.
- Preserved cognition: Critically, intelligence is not significantly affected in most people with AT. IQ is generally in the normal range. Children with AT understand their situation, have normal emotional depth, and can learn — even as their bodies become less and less cooperative. Educational support that accounts for physical limitations (not cognitive ones) is essential.
Telangiectasias: The Diagnostic Hallmark
The second part of the name — telangiectasia — refers to permanently dilated, spider-like clusters of small blood vessels that become visible through the skin and in the whites of the eyes. In AT, these appear most characteristically in the conjunctivae (the whites of the eyes), where they can be seen by any physician looking carefully with a light. They also appear on sun-exposed skin: the ears (particularly the helices), the back of the neck, the inner elbows (antecubital fossae), and the nose.
When Telangiectasias Appear
Telangiectasias typically emerge between ages 5 and 8 — notably after ataxia is already well-established. This timing means they are not useful for early diagnosis; by the time a child develops visible conjunctival telangiectasias, the neurological disease is already several years in. Their appearance does, however, clinch the diagnosis when it was previously uncertain.
The Pathognomonic Conjunctival Finding
Conjunctival telangiectasias in AT are considered pathognomonic — meaning their presence is so characteristic of AT that their appearance, combined with ataxia, is essentially diagnostic. They appear as reddish, spidery vessel networks at the limbal junction (where the white sclera meets the colored iris), spreading outward onto the sclera. They are not painful and do not affect vision, but they are unmistakable to an observer familiar with AT.
Telangiectasias do not affect organ function directly but serve as a permanent visual marker of the underlying vascular dysregulation that is part of AT's systemic biology. In the skin, they may become cosmetically bothersome but cause no medical harm. The dangerous manifestations of AT are the neurological, immunological, and oncological — not the vascular ones.
Immunodeficiency in AT
AT causes a combined T- and B-cell immunodeficiency — meaning both arms of the adaptive immune system are impaired. The severity varies considerably among patients; some have near-normal immune function while others have profound deficiencies. This variability makes AT immunology more nuanced than the immunodeficiency seen in conditions like severe combined immunodeficiency (SCID) or X-linked agammaglobulinemia (XLA).
Why the Immune System Fails in AT
The immune dysfunction in AT stems directly from the ATM gene's role in supervising the DNA rearrangements that immune cells need. Both T-cell receptor (TCR) and immunoglobulin (Ig) gene assembly require V(D)J recombination — a process of precisely cutting and rejoining DNA segments to generate immune diversity. ATM normally monitors these cuts and ensures they are repaired correctly. Without ATM, the rearrangements are error-prone, many immune cell precursors fail to survive development, and the resulting immune cell populations are numerically reduced and functionally impaired.
Thymic Hypoplasia and T-Cell Deficiency
The thymus — the organ where T cells mature — is hypoplastic (underdeveloped) in AT. This results in reduced numbers of circulating T cells, including both helper T cells (CD4+) and cytotoxic T cells (CD8+). Regulatory T-cell function may also be abnormal. The practical consequence is impaired cell-mediated immunity — reduced ability to fight viral infections and certain intracellular bacteria.
Antibody Deficiencies
B-cell function is also impaired. The most common finding is selective immunoglobulin A (IgA) deficiency, present in approximately 60% of AT patients — the same percentage seen in the general primary immunodeficiency population, but here it is part of a broader pattern rather than an isolated finding. Immunoglobulin E (IgE) levels are also frequently low or undetectable. Immunoglobulin G (IgG) subclass deficiencies are common, particularly IgG2 and IgG4, which are the subclasses responsible for responses to polysaccharide antigens. Total immunoglobulin G may be normal or mildly reduced. The net effect is poor antibody responses to encapsulated bacteria.
Recurrent Sinopulmonary Infections
The clinical consequence of AT immunodeficiency is recurrent sinopulmonary infections — recurring sinusitis, otitis media (ear infections), bronchitis, and pneumonia. The responsible organisms are the same encapsulated bacteria that cause recurrent infections in other antibody deficiencies: Streptococcus pneumoniae and Haemophilus influenzae. Over years, repeated pulmonary infections drive the development of bronchiectasis — permanent scarring and dilation of the airways — which becomes a major source of respiratory morbidity alongside the neurological decline.
Immune Findings and Survival
A retrospective cohort study of 61 AT patients, led from the Netherlands and published in 2017, found that people with classic AT had shorter survival than people with the milder variant form (hazard ratio 5.9, 95% confidence interval 2.0–17.7), especially once a cancer had been diagnosed (hazard ratio 2.5 compared with classic AT patients without cancer). Patients whose blood showed low immunoglobulin G together with a raised immunoglobulin M (IgM) pattern (the hyper-IgM phenotype with hypogammaglobulinemia) had shorter survival than patients with normal immunoglobulin G (hazard ratio 9.2, 95% confidence interval 3.2–26.5). Patients with IgG2 deficiency had shorter survival than patients with normal IgG2 levels (hazard ratio 7.8, 95% confidence interval 1.7–36.2). A hazard ratio above 1 means a higher death rate in the first group than in the group it is compared with.
Cancer Susceptibility and Radiation Sensitivity
AT carries one of the highest cancer risks of any inherited disease. The risk is not incidental — it is a direct and unavoidable consequence of ATM's role as the guardian of the genome. Without ATM to repair double-strand breaks and trigger apoptosis in severely damaged cells, mutations accumulate, chromosomal rearrangements propagate, and malignant clones emerge.
Magnitude of Cancer Risk
People with AT have a 100- to 1,000-fold elevated risk of developing lymphoma or leukemia compared to the general population. The most common malignancies are:
- T-cell lymphomas (including T-cell prolymphocytic leukemia, T-cell acute lymphoblastic leukemia)
- B-cell lymphomas (non-Hodgkin subtypes)
- Acute lymphoblastic leukemia (ALL)
A 1986 study of 263 AT patients, compared against United States mortality rates, put numbers on this risk. It counted 52 primary cancers: a 61-fold cancer excess in white patients and a 184-fold excess in Black patients. The excess was greatest for lymphoma, at 252-fold in white patients and 750-fold in Black patients. Deaths from all causes were 50 and 147 times the expected rate, respectively.
The cumulative cancer risk by age 20 is approximately 10%. Over a lifetime, roughly 30% of AT patients will develop a malignancy. Solid tumors also occur at higher rates, including breast cancer (relevant for adult survivors and for carriers — discussed below), brain tumors, and gastrointestinal cancers. Chromosomal instability in AT is particularly pronounced at the sites of the T-cell receptor genes on chromosomes 7 and 14, explaining the predominance of T-cell malignancies.
Radiation Hypersensitivity: A Critical Safety Issue
Radiation — whether diagnostic X-rays, computed tomography (CT) scans, or therapeutic radiation — causes DNA double-strand breaks as its primary mechanism of biological effect. In healthy cells, ATM immediately senses these breaks and coordinates repair. In AT cells, this repair does not happen. The result is that AT patients are exquisitely sensitive to ionizing radiation at doses that would be entirely safe for other people.
This has direct and urgent implications for medical care:
- Computed tomography scans carry a particular hazard. Computed tomography delivers substantially more radiation than plain X-rays. In AT patients, the radiation from a computed tomography scan creates DNA damage that cannot be repaired normally. Magnetic resonance imaging (MRI) and ultrasound use no ionizing radiation. Emergency doctors, radiologists, and surgeons who have not been told about the diagnosis have no way of knowing about this sensitivity.
- Radiotherapy is contraindicated. Standard radiation therapy for cancer delivers doses that would be lethal to AT cells. When radiotherapy is considered (for a malignancy that has developed), it is either left out entirely or delivered at dramatically reduced doses with extraordinary caution.
- Chemotherapy is modified. Many standard chemotherapy drugs — including alkylating agents and anthracyclines — work by causing DNA double-strand breaks. In AT patients, these agents cause disproportionately severe toxicity. Chemotherapy protocols are modified, typically reducing doses of DNA-damaging agents by 25–50%, when a malignancy requires treatment. Standard-dose chemotherapy has caused fatal toxicity in AT patients.
Alpha-Fetoprotein and Diagnosis
One of the most practical and accessible diagnostic clues in AT is a simple blood test: serum alpha-fetoprotein (AFP). AFP is a protein normally produced by the fetal liver and yolk sac; levels are high at birth and fall to adult-normal values (below 10 ng/mL) by about 12 months of age. In AT patients, AFP levels remain persistently elevated beyond infancy and stay high throughout life — typically in the range of 10–2,000 ng/mL. In a 2026 Dutch cohort of 45 AT patients (336 AFP measurements), levels in classic AT rose until about age 18 and then levelled off at 34 to 1,000 µg/L (micrograms per litre, the same as ng/mL).
AFP as a Hallmark Biomarker
Elevated AFP is found in approximately 95% of AT patients, making it one of the most sensitive biomarkers for the condition. The exact mechanism for persistent AFP elevation in AT is not fully understood, but it is thought to reflect ongoing hepatocellular stress or abnormal liver regeneration related to ATM dysfunction in liver cells.
The combination of elevated AFP + low or absent immunoglobulin A + progressive ataxia beginning in early childhood is a strong diagnostic signal. When a physician sees a young child with ataxia and measures AFP as part of the workup, a markedly elevated level points toward further AT-specific evaluation.
Full Diagnostic Workup
A complete diagnostic evaluation for AT includes:
- Serum AFP: Elevated in 95%. In the 2026 Dutch cohort, AFP could still fall within the age-based normal range in the first two years of life; no normal AFP level was seen in anyone with classic AT over the age of 3 years.
- Serum immunoglobulins (IgA, IgG, IgM, IgE): IgA absent or very low in ~60%; IgG subclass deficiencies common; IgE typically low.
- Lymphocyte subset counts: T-cell lymphopenia (reduced CD4+ and/or CD8+ T cells).
- Chromosomal instability study: Peripheral blood lymphocytes exposed to X-irradiation show markedly elevated chromosomal breaks, particularly at the T-cell receptor gene loci on chromosomes 7 and 14 — a pattern highly characteristic of AT.
- ATM protein expression (Western blot): Performed on cultured fibroblasts or lymphoblasts. In classic AT, ATM protein is absent or markedly reduced. This test can distinguish AT from milder ATM variant syndromes.
- ATM gene sequencing: Confirms the diagnosis, identifies the specific mutations (most AT patients are compound heterozygous — carrying two different ATM mutations), enables carrier testing of parents and siblings, and makes prenatal diagnosis possible in future pregnancies.
- Brain magnetic resonance imaging: Shows cerebellar atrophy in established AT; useful for excluding other treatable causes of ataxia early in the workup.
There is no single definitive test; the diagnosis rests on the clinical picture combined with several supporting laboratory findings. Early genetic diagnosis allows appropriate management to begin sooner and protects the patient from radiation exposures that might otherwise occur during the diagnostic workup itself.
Treatment and Supportive Care
There is currently no disease-modifying therapy for AT that halts or reverses the underlying ATM dysfunction. Research into potential therapies — including read-through drugs for nonsense mutations, ATM activators, and gene therapy approaches — is active but has not yet produced clinical treatments. Management is therefore entirely supportive, aimed at preventing complications, treating infections aggressively, and maintaining function and quality of life as long as possible.
Dexamethasone in Red Blood Cells: Two Phase 3 Trials
Steroid medicines (corticosteroids) can improve neurological function in AT, but suppression of the adrenal glands and the return of symptoms once they are stopped have limited their use, the authors of the ATTeST trial write. Two large placebo-controlled phase 3 trials therefore tested dexamethasone sodium phosphate sealed inside the patient's own red blood cells and given into a vein about once a month for six doses.
- ATTeST (2024): 175 children aged 6 years or older received at least one dose of a low dose, a high dose or placebo. Neither dose changed the ataxia rating score (the modified International Cooperative Ataxia Rating Scale) at 6 months compared with placebo. There were no reports of high blood sugar, high blood pressure, excess hair growth or a Cushing-like appearance, and no treatment-related deaths.
- NEAT (2026): 105 children received the treatment or placebo, and the main analysis looked at those aged 6–9 years. The change in the ataxia score at 6 months did not differ significantly from placebo. There were no treatment-related serious adverse events or deaths, and laboratory tests showed no harmful effects on growth, metabolism, bone mineral density or hormone (endocrine) function.
Immunoglobulin Replacement
For AT patients with documented humoral immunodeficiency and recurrent sinopulmonary infections, immunoglobulin replacement therapy (either intravenous immunoglobulin (IVIG) given every 3–4 weeks or subcutaneous immunoglobulin (SCIG) given weekly at home) replaces the immunoglobulin G antibodies the patient's B cells cannot reliably produce. The goal is to maintain immunoglobulin G trough levels above 5–7 g/L, reducing the frequency and severity of bacterial infections. Not every AT patient requires immunoglobulin replacement — it is reserved for those who have demonstrated deficient antibody levels plus significant infectious morbidity.
Infection Prevention and Treatment
Antibiotic prophylaxis — typically with trimethoprim-sulfamethoxazole (TMP-SMX) — is used in patients with recurrent bacterial infections to reduce the frequency of sinopulmonary episodes. When infections do occur, aggressive antibiotic treatment aims to prevent the cumulative lung damage that leads to bronchiectasis; each new respiratory infection is a chance for that damage to build up.
Pulmonary Care
Preserving lung function is a priority. Annual spirometry (lung function testing) tracks respiratory decline. Chest physiotherapy — techniques to help clear mucus from the airways — is taught to patients and families for regular use at home. Bronchodilators (inhalers) help open constricted airways. Once bronchiectasis is established, an airway clearance device (such as an oscillating positive expiratory pressure device) may be added to the daily routine. Cigarette smoke exposure adds further strain on the airways.
Neurological and Rehabilitation Support
Physical therapy (PT) helps maintain strength, balance, and mobility for as long as possible and guides the transition to adaptive equipment. Occupational therapy (OT) assists with adaptations for daily living — modified utensils, communication aids, and environmental modifications that support independence. Speech therapy addresses dysarthria and, if swallowing difficulties develop, helps prevent aspiration. When walking becomes unsafe, the transition to a powered wheelchair preserves independence and reduces injury risk from falls.
Radiation Avoidance — A Daily Priority
A medical alert card that explains the diagnosis and the sensitivity to ionizing radiation (including computed tomography scans and X-ray-based imaging) tells every doctor, nurse, and radiologist involved in care about it at once — including emergency and urgent care providers who may not know the patient. When imaging cannot wait in an emergency, a plain X-ray gives a far smaller dose than computed tomography; magnetic resonance imaging and ultrasound use no ionizing radiation at all.
Cancer Treatment When Malignancy Develops
When a cancer develops in an AT patient, treatment requires close collaboration between oncologists experienced in AT and the patient's primary care team. Standard chemotherapy protocols are modified — DNA-damaging agents (alkylators, anthracyclines, topoisomerase inhibitors) are typically dose-reduced by 25–50%. Standard radiotherapy doses are contraindicated; treatment plans use reduced-dose radiation or no radiation at all. Hematopoietic stem cell transplantation (HSCT) is an option for certain leukemias, weighed by centers experienced in AT. Immune checkpoint inhibitors have been used in some AT malignancies.
Cancer Surveillance
Given the high cancer risk, systematic cancer surveillance for AT patients typically includes: annual physical examination with lymph node evaluation, low-threshold investigation of lymphadenopathy, baseline and periodic complete blood count (CBC) to detect cytopenias suggesting marrow infiltration, and clinical evaluation of any unexplained constitutional symptoms (fever, night sweats, weight loss). Abdominal ultrasound can detect splenomegaly. The goal is early detection, when treatment options are broader.
Heterozygous ATM Carriers: Family Risk
Because AT is autosomal recessive, every person with AT has two parents who are obligate heterozygous ATM carriers — they carry one normal ATM gene and one defective copy. Siblings of an AT patient each have a 50% chance of being a carrier. With an estimated carrier frequency of approximately 1% of the general population, heterozygous ATM variants are among the most common disease-relevant gene variants in humans.
Carriers Do Not Have AT
Heterozygous carriers — one working copy of ATM — have enough ATM protein to function essentially normally. They do not develop the neurological, immune, or childhood-onset features of AT. A carrier who does not have a child with AT may never know they carry the mutation.
Elevated Cancer Risk in Carriers
However, carriers are not entirely unaffected. Research has established that heterozygous ATM mutation carriers have an elevated risk of breast cancer — approximately 2- to 3-fold compared to the general population. This places ATM carriers in an intermediate risk category, below the very high risk of BRCA1/2 mutation carriers but meaningfully above population baseline. The mechanism is the reduced ATM protein level in carrier cells, which impairs (but does not eliminate) DNA double-strand break repair capacity in the breast epithelium.
Estimates of how large the risk is differ between studies. A 2016 meta-analysis of 19 studies estimated the cumulative breast cancer risk in ATM carriers at 6.02% by age 50 (95% credible interval 4.58–7.42%) and 32.83% by age 80 (95% credible interval 24.55–40.43%). A 2022 population-based Australian family study estimated 13% by age 80 (95% confidence interval 4.6–30); its hazard ratio of 1.32 (95% confidence interval 0.45–3.87) was not statistically significant. A 2021 analysis of 60,466 women with breast cancer and 53,461 women without it confirmed that protein-truncating ATM variants are associated with breast cancer risk, with higher odds ratios for estrogen-receptor-positive than for estrogen-receptor-negative disease.
Measures discussed for ATM carriers typically include:
- Awareness of the elevated breast cancer risk, with discussion of enhanced surveillance (annual mammography and consideration of magnetic resonance imaging) based on individual risk factors and family history.
- Modest caution regarding unnecessary ionizing radiation exposures — carriers have slightly increased radiation sensitivity compared to the general population, though this is far less severe than in AT patients themselves.
- Genetic counseling when planning families, particularly if a partner may also be a carrier (relevant if there is a family history of AT, consanguinity, or a known carrier status in the community).
Carrier Testing and Counseling
ATM gene sequencing is available and can identify carriers in families where the specific AT mutations are known. For families who have had an AT-affected child, carrier testing of parents and adult siblings shows who carries one of the family's ATM variants. Prenatal testing in future pregnancies is possible by chorionic villus sampling or amniocentesis once both parental mutations are identified.
Living with AT: Practical Guidance
Raising a child with AT, or living with AT as a young adult, involves navigating a healthcare system that often has limited familiarity with the condition, while managing the physical realities of progressive disability alongside the emotional weight of a serious multi-system disease. Several practical points can make a meaningful difference in day-to-day quality of life.
Communicating with the Medical Team
The most dangerous single scenario for an AT patient in a healthcare encounter is an uninformed clinician ordering a computed tomography scan or administering standard-dose chemotherapy. Every visit to a doctor, emergency room, or specialist is an opportunity for miscommunication. An up-to-date one-page medical summary that lists the AT diagnosis, the most critical management points (no computed tomography scans, modified chemo protocols, no live vaccines), current medications, and contact information for the patient's immunologist and neurologist, carried to every medical appointment, puts this information in front of each new clinician.
School and Education
Children with AT have normal intelligence but progressive physical disability. An Individualized Education Plan (IEP) or 504 accommodation plan can address mobility aids (wheelchair access, elevator access), extended time for written work (coordination problems slow handwriting), speech assistance (dysarthria), and accommodations for fatigue. Voice-to-text software and tablet devices that reduce reliance on fine motor skills can significantly expand what a child with AT can accomplish academically.
Emotional and Psychological Support
AT does not impair intellect, which means children and young adults with AT fully understand what is happening to their bodies. The emotional burden — awareness of progressive disability, limited life expectancy, cancer risk — is real and significant. Mental health support, whether through a therapist familiar with chronic illness, peer support from other AT families, or family counseling, is as important as any medical intervention.
A-T Children's Project and Patient Organizations
The A-T Children's Project and the National Ataxia Foundation provide family support networks, research funding information, physician referral assistance, and educational materials specific to AT. Connecting with these organizations early — at the time of diagnosis — gives families access to a community with hard-won practical knowledge and a pipeline to emerging research.
Research and Clinical Trials
Active research areas in AT include read-through drugs (which allow ribosomes to skip premature stop codons, relevant for the ~30% of AT mutations that are nonsense variants), small-molecule ATM activators, gene therapy approaches, and novel cancer treatment protocols adapted to the AT context. AT-specific studies and their eligibility rules are listed on ClinicalTrials.gov.
Key Research Papers
- Savitsky K et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995. — PubMed PMID: 7792600
- Lavin MF, Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol. 1997. — PubMed PMID: 9143686
- Taylor AM, Harnden DG, Arlett CF, et al. Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature. 1975. — PubMed PMID: 1196376
- Gatti RA, Berkel I, Boder E, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature. 1988. — PubMed PMID: 3200306
- Boder E, Sedgwick RP. Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics. 1958. — PubMed PMID: 13542097
- Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and treatment. Semin Pediatr Neurol. 2003. — PubMed PMID: 14653405
- Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst. 1986. — PubMed PMID: 3459930
- Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood. 2013. — PubMed PMID: 23440242
- Marabelli M, Cheng SC, Parmigiani G. Penetrance of ATM gene mutations in breast cancer: a meta-analysis of different measures of risk. Genet Epidemiol. 2016. — PubMed PMID: 27112364
- Renault AL, Dowty JG, Steen JA, et al. Population-based estimates of age-specific cumulative risk of breast cancer for pathogenic variants in ATM. Breast Cancer Res. 2022. — PubMed PMID: 35365198
- Breast Cancer Association Consortium; Dorling L, Carvalho S, Allen J, et al. Breast cancer risk genes - association analysis in more than 113,000 women. N Engl J Med. 2021. — PubMed PMID: 33471991
- Veenhuis SJG, van Os NJH, Swinkels AEH, Weemaes CMR, Roeleveld N, Willemsen MAAP. Serum alpha fetoprotein in Ataxia Telangiectasia: new lessons about an old biomarker. Eur J Paediatr Neurol. 2026. — PubMed PMID: 41844009
- van Os NJH, Jansen AFM, van Deuren M, et al. Ataxia-telangiectasia: immunodeficiency and survival. Clin Immunol. 2017. — PubMed PMID: 28126470
- Staples ER et al. Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene. Clin Exp Immunol. 2008. — PubMed PMID: 18505428
- Zielen S, Crawford T, Benatti L, et al. Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2024. — PubMed PMID: 39152028
- Russo S, Zielen S, Pietrucha B, et al. Neurological effects of encapsulated dexamethasone sodium phosphate in children aged 6-9 years with ataxia telangiectasia (NEAT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Child Adolesc Health. 2026. — PubMed PMID: 42600624
Search PubMed for more: Ataxia-Telangiectasia on PubMed